canada rx
Make a Difference with a Donation

CEGIR


The Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) is dedicated to improving the lives of individuals with eosinophilic gastrointestinal disorders through innovative research, clinical expertise and education via collaborations between scientists, health care providers, patients, and professional organizations. The disorders CEGIR focuses on are eosinophilic esophagitis (EoE), eosinophilic gastritis (EG) and eosinophilic colitis (EC). The team has a multidisciplinary approach and integrates expertise in pediatric and adult clinical specialties, including gastroenterology, allergy, immunology and pathology. Funded by the National Institutes of Health (NIH), CEGIR is part of the Rare Diseases Clinical Research Network (RDCRN).
Overall Goals
Improve the lives of individuals with eosinophilic gastrointestinal disorders
Facilitate research on eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), and eosinophilic colitis (EC) through the development of a Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)
Establish a EGID Patient Contact Registry
Develop and maintain a website with information for scientists, health care providers, patients, and professional organizations
Clinical Research Project 1 Goals
Determine the correlation of clinical outcome measures (COMs) and patient-reported outcomes (PROs) with the histological disease activity as measured by mucosal eosinophil counts
Develop a new gold standard for EoE, EG, and/or EC diagnosis and monitoring
Determine the correlation of the molecular profile for EoE, EG, and EC with COMs and mucosal eosinophilia
Clinical Research Project 2 Goals
Optimize treatment of EoE with readily available therapies (diet and steroids)
Develop a personalized medicine approach based on biomarker analysis that can predict the best treatment for individual patients
Evaluate the efficacy of different restricted diets and determine whether patients who experience diet failure remain responsive to swallowed glucocorticoids (SGC) therapy
Pilot/Demonstration Clinical Research Program Goals
Support new ideas that have potential to create and/or change paradigms concerning EoE, EG, and EC
Training (Career Development) Program Goals
Train new investigators in clinical and translational research, enhancing the likelihood of academic success for the investigators in training
Enable CEGIR Trainees to become independent clinical and/or translational investigators
Aid CEGIR Trainees in developing a broad understanding of the basic, translational, and clinical science pertinent to the immunobiology, pathogenesis, and genetics of EoE, EG, and EC via didactic instruction
Facilitate CEGIR Trainee networking and integration in the EoE, EG, and EC research community
Patient Advocacy Goals
In collaboration with our partner Patient Advocacy Groups (PAGs):
Develop efficient pathways to communicate the latest clinical and research developments to patients and their families (via websites, social media, newsletters, conferences, contact registries)
Offer a forum for the collection and dissemination of patient and family perspectives and priorities
Offer public educational initiatives to raise awareness of and quality of care for eosinophilic GI diseases
Industry Collaboration Goals
Partner with industry in order to improve the lives of patients with EGIDs, including conducting clinical trials

CEGIR GRANT RFA
Request for Applications Open for CEGIR Grant
The CEGIR grant (U54 AI117804) affords the opportunity to train experts through establishing a much-needed training program for these rare diseases.

CEGIR releases this Request for Applications (RFA) for Training Awards to physicians (fellows-in-training and junior faculty) interested in developing expertise in performing research in and providing outstanding clinical care for EGIDs.
Deadline April 18, 2018
CEGIR-Training-RFA-2018


Clinical Studies
CEGIR PARTNERS WITH CEGIR

CURED both supports and is a part of the Consortium of Eosinophilic Gastrointestinal Researchers (CEGIR). CEGIR was founded in Fall 2014 with an NIH grant (U54 AI117804) and is believed to be the first to establish a network focusing on the three distinct diseases of eosinophilic esophagitis, eosinophilic gastritis, and eosinophilic colitis. CEGIR furthers research and clinical expertise, trains clinical investigators, supports pilot clinical research projects, and provides access to information related to eosinophilic disorders for basic and clinical researchers, physicians, patients, and the lay public. The grant is funded by the Office of Rare Diseases Research, which is part of the NIH’s National Center for Advance Translational Studies, as part of the Rare Disease Research Network. This award is co-funded by the National Center for Advancing Translational Sciences, National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institute of Allergy and Infectious Diseases. CURED is one of the patient advocacy organizations that contributes meaningfully by leading from within CEGIR and also donates $25 thousand to CEGIR’s initiatives. Coinciding with Rare Disease Day® 2015, CEGIR launched a patient contact registry for individuals with eosinophilic gastrointestinal diseases. The registry is located at www.rdcrn.org/CEGIR, and its purpose is to create a single, international database with information submitted by patients and their families. Establishing such a database will enable CEGIR investigators to identify and recruit patients for new research studies directed towards improving treatments and clinical care.

CEGIR REGISTRY
“The Patient Contact Registry is a critical tool to help advance EGIDs research efforts. CURED is actively involved in the work CEGIR is doing and we are excited to encourage the use of the registry. This is an important and exciting development for the EGID community. Patients and parents want to hear about the research, they want to be asked for their input – they want to be active participants in the research process. This registry offers our patient community the opportunity to have substantially greater visibility to ongoing studies and to have that information placed directly in their inbox. We strongly encourage everyone who has been diagnosed with an EGID to enroll.” – Ellyn Kodroff, President and Founder of CURED
Why should you register with CEGIR?
REGISTER HERE

SSL Certificate security seal

http://americanbestpills.com/